ACE-031, at a strength of 1mg, is presently generating significant interest across Europe. Preliminary clinical studies in countries such as the Federal Republic of Germany, France and its neighbors, and the United Kingdom have shown encouraging results in treating particular neurological conditions. Regulatory bodies across the area are thoroughly